Aps Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 8.40 M
as on 31-07-2024
- Company Age 19 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 8.10 M
as on 31-07-2024
- Revenue 2.74%
(FY 2023)
- Profit 11.15%
(FY 2023)
- Ebitda 0.10%
(FY 2023)
- Net Worth 8.72%
(FY 2023)
- Total Assets -0.16%
(FY 2023)
About Aps Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.40 M.
The company has closed loans amounting to ₹8.10 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pawankumar Agarwal, Anil Narnoli, Shailesh Agarwal, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24230UR2005PTC007161
- Company No.
007161
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Oct 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Roorkee, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Aps Biotech?
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawankumar Agarwal  | Director | 11-Oct-2005 | Current |
| Anil Narnoli | Director | 03-Jul-2006 | Current |
| Shailesh Agarwal | Director | 11-Oct-2005 | Current |
| Mahesh Megotia | Director | 30-Oct-2005 | Current |
| Prem Megotia | Director | 13-Mar-2015 | Current |
| Anand Agarwal | Director | 13-Mar-2015 | Current |
Financial Performance of Aps Biotech.
Aps Biotech Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.74% increase. The company also saw a substantial improvement in profitability, with a 11.15% increase in profit. The company's net worth moved up by a moderate rise of 8.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aps Biotech?
In 2023, Aps Biotech had a promoter holding of 54.76% and a public holding of 45.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 07 Mar 2014 | ₹0.60 M | Satisfied |
Union Bank Of India Creation Date: 17 Jan 2007 | ₹7.50 M | Satisfied |
How Many Employees Work at Aps Biotech?
Aps Biotech has a workforce of 21 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aps Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aps Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
